Journal
CLINICAL KIDNEY JOURNAL
Volume 12, Issue 3, Pages 322-325Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ckj/sfz019
Keywords
chronic kidney disease; diabetic nephropathy; SGLT2; type 2 diabetes
Categories
Funding
- FONDO DE INVESTIGACION SANITARIA-FEDER, ISCIII [PI17/00257]
- REDINREN [RD16/0009/0030]
Ask authors/readers for more resources
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes. The glycaemic control exerted by these drugs is not greater than the one achieved with other classical glucose-lowering medications such as sulphonylureas. For that reason, plausible renoprotective mechanisms independent from glycaemic control have been proposed such as blood pressure control, body weight loss, intraglomerular pressure reduction and a decrease in urinary proximal tubular injury biomarkers. Interestingly, the hypothesis that SGLT2 inhibitors have a direct renoprotective effect has been addressed in diabetic and non-diabetic models. In this editorial, we update the different postulated mechanisms involved in the cardiorenal protection afforded by SGLT2 inhibition in chronic kidney disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available